tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ramachandran R et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial. 2016 Nephrology (Carlton) pmid:26205759
Lee YJ et al. Acquired Bilateral Dyspigmentation on Face and Neck: Clinically Appropriate Approaches. 2016 J. Korean Med. Sci. pmid:27822947
Khan S et al. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization. 2016 Eur J Pharm Biopharm pmid:27449630
Tomei P et al. Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. 2016 J. Nephrol. pmid:27026415
Klein OR et al. Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. 2016 Biol. Blood Marrow Transplant. pmid:26860634
Jahnukainen T et al. The second report of the Nordic Pediatric Renal Transplantation Registry 1997-2012: More infant recipients and improved graft survivals. 2016 Pediatr Transplant pmid:26857893
Kanda Y et al. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. 2016 Bone Marrow Transplant. pmid:26437063
Mok MM et al. Acute Phosphate Nephropathy: An Under-Recognized Complication Leading to Impaired Allograft Function After Renal Transplant. 2016 Nephrology (Carlton) pmid:27730726
Stocki P et al. Inhibition of the FKBP family of peptidyl prolyl isomerases induces abortive translocation and degradation of the cellular prion protein. 2016 Mol. Biol. Cell pmid:26764098
Kawamura A et al. Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice. 2016 Sci Rep pmid:26763872
Suh SW et al. Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients. 2016 J. Korean Med. Sci. pmid:27709847
Kim JM et al. Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection. 2016 Clin Mol Hepatol pmid:27729628
Michael M et al. Outcomes of two-drug maintenance immunosuppression for pediatric renal transplantation: 10-yr follow-up in a single center. 2016 Pediatr Transplant pmid:26916966
Treister N et al. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. 2016 Biol. Blood Marrow Transplant. pmid:27590106
Kabat-Koperska J et al. The influence of exposure to immunosuppressive treatment during pregnancy on renal function and rate of apoptosis in native kidneys of female Wistar rats. 2016 Apoptosis pmid:27586504
Jun H et al. Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients. 2016 Int J Clin Pharmacol Ther pmid:26709601
Schmutz JL [No increased risk of cancer under pimecrolimus]. 2016 Ann Dermatol Venereol pmid:26708204
Valbuena H et al. Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. 2016 Clin. Chem. Lab. Med. pmid:26351941
Tamaki M et al. Fungal meningitis caused by Lomentospora prolificans after allogeneic hematopoietic stem cell transplantation. 2016 Transpl Infect Dis pmid:27258644
Wang L et al. Therapeutic advances for primary biliary cholangitis: the old and the new. 2016 Eur J Gastroenterol Hepatol pmid:26862931
Ben Fredj N et al. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. 2016 Exp Clin Transplant pmid:27506258
Miyata Y et al. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms. 2016 Ann. Transplant. pmid:27503662
Orr C et al. Quantifying Insulin Therapy Requirements to Preserve Islet Graft Function Following Islet Transplantation. 2016 Cell Transplant pmid:25853639
Yaowakulpatana K et al. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation. 2016 Eur. J. Clin. Pharmacol. pmid:26635230
Griffin SP and Nelson JE Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients. 2016 Prog Transplant pmid:27628498
Faraj W et al. Osteoporosis in Pediatric Liver Transplantation. 2016 Prog Transplant pmid:27555069
Gastaca M et al. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. 2016 Liver Transpl. pmid:27434676
Genvigir FD et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. 2016 Pharmacogenet. Genomics pmid:27434656
Qi XM et al. FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats. 2016 Inflamm. Res. pmid:26566632
Seo J et al. Therapeutic advantage of inhaled tacrolimus-bound albumin nanoparticles in a bleomycin-induced pulmonary fibrosis mouse model. 2016 Pulm Pharmacol Ther pmid:26768967
Miura K et al. Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. 2016 Transplant. Proc. pmid:27320612
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Yesilipek MA et al. Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: A single-center study. 2016 Pediatr Transplant pmid:26707539
Weiner SM [Combination of tacrolimus and MMF for treatment of proliferative lupus nephritis]. 2016 Z Rheumatol pmid:27259912
Sobiak J et al. Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. 2016 Eur J Drug Metab Pharmacokinet pmid:25663618
Hannun P et al. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. 2016 Ther Drug Monit pmid:26919549
Medeiros M et al. Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage? 2016 Ther Drug Monit pmid:27167176
Abud TB et al. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. 2016 Ophthalmology pmid:27086024
Nijhoff MF et al. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. 2016 Am. J. Transplant. pmid:26288226
Otte JB Pediatric liver transplantation: Personal perspectives on historical achievements and future challenges. 2016 Liver Transpl. pmid:27096329
Anuradha D and Parsad FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. 2016 Dermatol Ther pmid:27093927
Muduma G et al. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. 2016 J Med Econ pmid:27172118
Tannuri AC et al. Prognostic factors for the evolution and reversibility of chronic rejection in pediatric liver transplantation. 2016 Clinics (Sao Paulo) pmid:27166772
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Alagoz S et al. Gangliocytoma Presenting With Tacrolimus Neurotoxicity in a Renal Transplant Recipient: Case Report. 2016 Transplant. Proc. pmid:27932167
Kolonko A et al. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. 2016 Transplant. Proc. pmid:27932154
Sugitani A et al. Unusual case of tacrolimus vascular toxicity after deceased donor renal transplantation. 2016 Nephrology (Carlton) pmid:27004749
Thölking G et al. Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation. 2016 Ann. Transplant. pmid:27003330
Krämer BK et al. Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-year observational results. 2016 Transpl. Int. pmid:26565071
Janicki JJ et al. Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. 2016 Toxins (Basel) pmid:26999210